Drug Repositioning of Cardiac Steroids as Potential Agents for the Treatment of Triple‑Negative Breast Cancer.
Data support digitoxigenin as a prioritized cardiac steroid scaffold that combines potent in vitro cytotoxicity with improved selectivity and a more favorable drug-likeness profile than digitoxin, while the in silico analyses provide a mechanistic hypothesis centered on angiogenesis and survival signaling.